Cited by 2,077Heart Failure Treatment and ManagementCardiovascular Function and Risk FactorsCardiac Fibrosis and Remodeling

The DOI matches its Crossref record; 143 of the 144 references it cites were found in a registry or an index.

Epidemiology and risk profile of heart failure

Open access

Bui, Anh L., Horwich, Tamara B., Fonarow, Gregg C.·2011·Nature Reviews Cardiology

DOI 10.1038/nrcardio.2010.165PMC PMC3033496

Open this paper in CoChat — free account

Abstract

Heart failure (HF) is a major public health issue, with a prevalence of over 5.8 million in the USA, and over 23 million worldwide, and rising. The lifetime risk of developing HF is one in five. Although promising evidence shows that the age-adjusted incidence of HF may have plateaued, HF still carries substantial morbidity and mortality, with 5-year mortality that rival those of many cancers. HF represents a considerable burden to the health-care system, responsible for costs of more than $39 billion annually in the USA alone, and high rates of hospitalizations, readmissions, and outpatient visits. HF is not a single entity, but a clinical syndrome that may have different characteristics depending on age, sex, race or ethnicity, left ventricular ejection fraction (LVEF) status, and HF etiology. Furthermore, pathophysiological differences are observed among patients diagnosed with HF and reduced LVEF compared with HF and preserved LVEF, which are beginning to be better appreciated in epidemiological studies. A number of risk factors, such as ischemic heart disease, hypertension, smoking, obesity, and diabetes, among others, have been identified that both predict the incidence of HF as well as its severity. In this Review, we discuss key features of the epidemiology and risk profile of HF.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrcardio.2010.165

Cites

143 of 143 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,824
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
HEART DISEASE AND STROKE STATISTICS–2014 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION
Tarver, T. (2014) · Journal of Consumer Health on the Internet · doi:10.1080/15398285.2014.902284 · Cited by 5,595
Rehospitalizations among Patients in the Medicare Fee-for-Service Program
Jencks, S. F., Williams, M. V., & Coleman, E. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0803563 · Cited by 5,164
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,109
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,209 · cited 1×
“HF and preserved LVEF now represents >50% of HF cases and can have outcomes as poor as those associated with HF and reduced LVEF, but it does not yet have a proven effective management strategy”
Background
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,137
Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
Swedberg, K. B., & KJEKSHUS, J. K. (1988) · The American Journal of Cardiology · doi:10.1016/s0002-9149(88)80087-0 · Cited by 3,762
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652

Show all 144 references

Research works printed but not linked: 1

Gordis, L. Epidemiology 37–84 (Elsevier/Saunders, Philadelphia, 2009).

Sorted by citations

Items 701–800 of 1,002

The role of the glypican and syndecan families of heparan sulfate proteoglycans in cardiovascular function and disease
Thota, L. N., & Chignalia, A. Z. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00018.2022 · Cited by 23
Data-driven identification of heart failure disease states and progression pathways using electronic health records
Nagamine, T., Gillette, B. M., Kahoun, J., Burghaus, R., Lippert, J., & Saxena, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-22398-4 · Cited by 23
Renal Tubular Damage and Clinical Outcome in Heart Failure with Preserved Ejection Fraction and Chronic Kidney Disease
Otaki, Y., Watanabe, T., Shimizu, M., Tachibana, S., Sato, J., Kobayashi, Y., Saito, Y., Aono, T., Tamura, H., Kato, S., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14378 · Cited by 24
“Despite advances in heart failure (HF) treatment, HF remains a public health problem associated with high morbidity and mortality.(1) Among the HF subtypes, HF with preserved ejection fraction (HFpEF) is an unmet medical need due to its increasing prevalence, high morbidity, and mortality.”
Background
Automated heart disease prediction using improved explainable learning-based technique
Bizimana, P. C., Zhang, Z., Hounye, A. H., Asim, M., Hammad, M. A., & El‐Latif, A. A. A. (2024) · Neural Computing and Applications · doi:10.1007/s00521-024-09967-6 · Cited by 25
A Novel Approach for the Effective Prediction of Cardiovascular Disease Using Applied Artificial Intelligence Techniques
Mir, A., Rehman, A. U., Ali, T. M., Javaid, S., Almufareh, M. F., Humayun, M., & Shaheen, M. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14942 · Cited by 23
Cardiovascular Risk and Quality of Life in Elderly People with Mild Thyroid Hormone Deficiency
Tognini, S., Pasqualetti, G., Calsolaro, V., Polini, A., Caraccio, N., & Monzani, F. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00153 · Cited by 23
“More than 20 million people suffer from HF worldwide (63), and its prevalence and incidence are increasing mostly because of increasing lifespan, and also because of increased prevalence of risk factors (diabetes mellitus, systemic hypertension, dyslipidemia) and improved survival rates from other types of CV diseases…”
Background
Ginseng (Panax quinquefolius) Attenuates Leptin-Induced Cardiac Hypertrophy through Inhibition of p115Rho Guanine Nucleotide Exchange Factor-RhoA/Rho-Associated, Coiled-Coil Containing Protein Kinase-Dependent Mitogen-Activated Protein Kinase Pathway Activation
Moey, M., Rajapurohitam, V., Zeidan, A., & Karmazyn, M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.182600 · Cited by 23
“, 2007) along with the detrimental accompanying risks for the development of cardiovascular disease (Bui et al., 2011).”
Background
PROspective MEmory Training to improve HEart failUre Self-care (PROMETHEUS): study protocol for a randomised controlled trial
Cameron, J., Rendell, P. G., Ski, C. F., Kure, C., McLennan, S. N., Rose, N. S., Prior, D., & Thompson, D. R. (2015) · Trials · doi:10.1186/s13063-015-0721-2 · Cited by 24
“risk for high morbidity and mortality [2].”
Current Pharmacological Therapies in Heart Failure Patients
Muiesan, M. L., Paini, A., Rosei, C. A., Bertacchini, F., Stassaldi, D., & Salvetti, M. (2017) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-017-0194-3 · Cited by 24
Proteomic Biomarkers of Heart Failure
Israr, M. Z., Heaney, L. M., & Suzuki, T. (2017) · Heart Failure Clinics · doi:10.1016/j.hfc.2017.08.010 · Cited by 23
Short- and Long-term Prognosis of Patients With Acute Heart Failure With and Without Diabetes: Changes Over the Last Three Decades
van den Berge, J. C., Constantinescu, A. A., Boiten, H. J., van Domburg, R. T., Deckers, J. W., & Akkerhuis, K. M. (2017) · Diabetes Care · doi:10.2337/dc17-0544 · Cited by 23
“Waiting for heart transplantation 35 (2) 4 (1) 31 (2) 0.”
Background
Is There a Cardiotoxicity Associated With Metallic Head Hip Prostheses? A Cohort Study in the French National Health Insurance Databases
Lassalle, M., Colas, S., Rudnichi, A., Zureik, M., & Dray‐Spira, R. (2018) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000533617.64678.69 · Cited by 23
“Conditions known to be or suspected of being associated with DCM or HF [1, 7, 24, 28, 29] were considered at baseline, namely cardiovascular comorbidities, psychiatric comorbidities, endocrinal and metabolic comorbidities, other comorbidities, drugs, and lifestyle factors.”
Background
Impact of clinical pharmacist engagement in ward teams on the number of drug-related readmissions among older patients with dementia or cognitive impairment: An economic evaluation
Sjölander, M., Lindholm, L. H., Pfister, B., Jonsson, J., Schneede, J., Lövheim, H., & Gustafsson, M. V. (2018) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2018.05.006 · Cited by 22
Palliative Care in Heart Failure
Ghashghaei, R., Yousefzai, R., & ADLER, E. D. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.01.002 · Cited by 22
Epidemiological and histological findings implicate matrix Gla protein in diastolic left ventricular dysfunction
Wei, F., Trenson, S., Monney, P. A., Yang, W., Pruijm, M. T., Zhang, Z., Bouatou, Y., Huang, Q., Ponte, B., Martin, P., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193967 · Cited by 22
“In view of the demographic transition, heart failure (HF) is a major public health problem [1].”
Background
T‐bet transcription factor in cardiovascular disease: Attenuation or inflammation factor?
Haybar, H., Rezaeeyan, H., Shahjahani, M., Shirzad, R., & Saki, N. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27935 · Cited by 22
Altered NK cell receptor repertoire and function of natural killer cells in patients with acute myocardial infarction: A three-month follow-up study
Ortega-Rodríguez, A. C., Marín-Jáuregui, L. S., Martínez-Shio, E. B., Hernández-Castro, B., González‐Amaro, R., Escobedo-Uribe, C. D., & Monsiváis-Urenda, A. E. (2020) · Immunobiology · doi:10.1016/j.imbio.2020.151909 · Cited by 22
Feasibility, repeatability, and reproducibility of contemporary diastolic parameters and classification
Bahrami, H. S. Z., Pedersen, F. H. G., Myhr, K. A., Møgelvang, R., & Hassager, C. (2021) · International journal of cardiac imaging · doi:10.1007/s10554-020-02069-z · Cited by 24
Association of Blood Pressure and Heart Rate Responses to Submaximal Exercise With Incident Heart Failure: The Framingham Heart Study
Carneiro, H. A., Song, R. J., Lee, J., Schwartz, B., Vasan, R. S., & Xanthakis, V. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019460 · Cited by 20
Analysis of Apps With a Medication List Functionality for Older Adults With Heart Failure Using the Mobile App Rating Scale and the IMS Institute for Healthcare Informatics Functionality Score: Evaluation Study
Diaz-Skeete, Y., McQuaid, D., Akinosun, A. S., Ekerete, I., Carragher, N., & Carragher, L. (2021) · JMIR mhealth and uhealth · doi:10.2196/30674 · Cited by 22
“Providing clear instructions on the use of an app is vital for older adults with HF. Patients with HF are predominantly patients aged ≥ 65 years [40], and old age has been cited as a barrier to app use and uptake [41].”
Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure
Perez-Belmonte, L. M., Sanz‐Cánovas, J., Millán‐Gómez, M., Osuna‐Sánchez, J., Sampalo, A. L., Ricci, M., Jiménez-Navarro, M. F., Lopez-Carmona, M. D., Bernal-López, M. R., Barbancho, M. Á., et al. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17585 · Cited by 22
“INTRODUCTION Heart failure (HF) is a major public health concern around the world and is associated with frequent hospitalizations and high mortality.(1,2) Sodium glucose cotransporter 2 (SGLT2) inhibitors have become recommended drugs for HF in patients with type 2 diabetes (T2D) for their positive results on various…”
Relationship Between Soluble Transferrin Receptor and Clinical Outcomes in Patients With Heart Failure According to Ejection Fraction Phenotype: The New Zealand PEOPLE Study
Fitzsimons, S., Poppe, K., Choi, Y. C., Devlin, G., Lund, M., Lam, C. S. P., Troughton, R. W., Richards, M., & Doughty, R. N. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.12.018 · Cited by 22
Neutrophil crosstalk during cardiac wound healing after myocardial infarction
Chalise, U., Becirovic‐Agic, M., & Lindsey, M. L. (2021) · Current Opinion in Physiology · doi:10.1016/j.cophys.2022.100485 · Cited by 22
Visualizing diastolic failure: Non-invasive imaging-biomarkers in patients with heart failure with preserved ejection fraction
Schulz, A., & Schuster, A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104369 · Cited by 22
Multiomic Spatial Mapping of Myocardial Infarction and Implications for Personalized Therapy
Schumacher, D., & Kramann, R. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318333 · Cited by 24
Novel drug targets in clinical development for heart failure
George, M., Rajaram, M., Shanmugam, E., & Vijayakumar, T. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1671-4 · Cited by 22
Cardiac metabolism in hypertrophy and heart failure: implications for therapy
Siddiqi, N., Singh, S., Beadle, R. M., Dawson, D. K., & Frenneaux, M. P. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9359-2 · Cited by 22
“The incidence of hospitalization with heart failure has dramatically increased in these countries over the past few decades [2], although there is evidence that age-specific rates may have peaked [3].”
Background
Heart Failure Hospitalization by Race/Ethnicity, Gender and Age in California: Implications for Prevention
Husaini, B. A., Levine, R. S., Norris, K. C., Cain, V. A., Bazargan, M., & Moonis, M. (2016) · Ethnicity & Disease · doi:10.18865/ed.26.3.345 · Cited by 22
Effects of Active Components of Fuzi and Gancao Compatibility on Bax, Bcl‐2, and Caspase‐3 in Chronic Heart Failure Rats
Wang, L., He, Y. T., Zhang, Y., Zhou, H., Yu, L., Yang, J., & Wan, H. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/7686045 · Cited by 23
“CHF is not a simple single disease, but the final stage of many heart diseases, with a series of clinical syndromes that may have been caused by myocardial hypertrophy, hypertension, ischemic heart disease, and so on [19, 20].”
Background
Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis
Zheng, X., Qu, Q., Jiang, X., Wang, Z., Tang, C., & Sun, J. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00441-x · Cited by 22
Impact of Clinical Characteristics and Management on the Prognosis of Unselected Heart Failure Patients
Eschalier, R., Chenaf, C., Mulliez, A., Yalioua, A., Clerfond, G., Authier, N., Vorilhon, C., Citron, B., Pereira, B., Jean, F., et al. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6572-y · Cited by 22
“to 500 per 100,000 patients between 1980 and 2000 [24].”
Interfacial tissue engineering of heart regenerative medicine based on soft cell-porous scaffolds
Geng, X., Liu, B., Liu, J., Liu, D., Lu, Y., Sun, X., Liang, K., & Kong, B. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.117 · Cited by 22
Cost-Effectiveness of Thoracotomy Approach for the Implantation of a Centrifugal Left Ventricular Assist Device
Mahr, C., McGee, E. C., Cheung, A. W., Mokadam, N. A., Strueber, M., Slaughter, M. S., Danter, M. R., Levy, W. C., Cheng, R. K.-H., Beckman, J. A., et al. (2020) · ASAIO Journal · doi:10.1097/mat.0000000000001209 · Cited by 21
Mechanism of long non‑coding RNA metastasis‑associated lung adenocarcinoma transcript 1 in lipid metabolism and inflammation in heart failure
Zhao, P., Wang, Y., Zhang, L., Zhang, J., Liu, N., & Wang, H. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4838 · Cited by 21
Sfrp1 protects against acute myocardial ischemia (AMI) injury in aged mice by inhibiting the Wnt/β-catenin signaling pathway
Tao, J., Wei, X., Huang, Y., Liu, F., Wu, Y., Adi, D., Xiang, Y., Chen, Y., Ma, Y., & Chen, B. (2021) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-020-01389-4 · Cited by 21
A Hybridized Model for the Prediction of Heart Disease using ML Algorithms
Naidu, T. P., Gopal, K. A., Ahmed, S. R., Revathi, R., Ahammad, S. H., Rajesh, V., Inthiyaz, S., & Saikumar, K. (2021) · International Conference on Advances in Computing, Communication Control and Networking (ICAC3N) · doi:10.1109/icac3n53548.2021.9725780 · Cited by 21
“Initial stages detection and diagnosis face complex issues mostly under developing countries, due to no province of diagnostic midpoints besides competent doctors in addition supplementary provinces need to accurately forecast the heart disease [3].”
Background
Remote monitoring in patients with heart failure with cardiac implantable electronic devices: a systematic review and meta-analysis
McGee, M., Ray, M., Brienesse, S. C., Sritharan, S., Boyle, A., Jackson, N., Leitch, J. W., & Sverdlov, A. L. (2022) · Open Heart · doi:10.1136/openhrt-2022-002096 · Cited by 21
Antisenescence Therapy Improves Function in a Human Model of Cardiac Fibrosis-on-a-Chip
Mourad, O., Mastikhina, O., Khan, S. T., Sun, X., Hatkar, R., Williams, K., & Nunes, S. S. (2023) · ACS Materials Au · doi:10.1021/acsmaterialsau.3c00009 · Cited by 23
Effect of coenzyme Q10 on cardiac function and survival in heart failure: an overview of systematic reviews and meta -analyses
Alarcón-Vieco, E., Martínez‐García, I., Sequí‐Domínguez, I., Rodríguez‐Gutiérrez, E., Moreno-Herráiz, N., & Pascual‐Morena, C. (2023) · Food & Function · doi:10.1039/d3fo01255g · Cited by 21
Quantitative Assessment of Left Ventricular Function by 3‐Dimensional Speckle‐Tracking Echocardiography in Patients With Chronic Heart Failure
Ma, C., Jiang, C., Yang, J., Tang, L., Chen, X., Li, N., Liu, S., & Zhang, Y. (2014) · Journal of Ultrasound in Medicine · doi:10.7863/ultra.33.2.287 · Cited by 21
“Eight assessment items relevant to the quality appraisal were used in this meta-analysis with scores ranging from 0 to 16: (1) adequacy of the case definition; (2) representativeness of the cases; (3) selection of controls; (4) definition of controls; (5) comparability of cases and controls on the basis of the design…”
Method
A Retrospective Observational Study of Anesthetic Induction Dosing Practices in Female Elderly Surgical Patients: Are We Overdosing Older Patients?
Akhtar, S., Heng, J., Dai, F., Schonberger, R. B., & Burg, M. M. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0394-x · Cited by 21
“Women are at higher risk of left ventricular hypertrophy and symptomatic heart failure with preserved ejection fraction [29, 31].”
Background
JDP2 overexpression provokes cardiac dysfunction in mice
Heger, J., Bornbaum, J., Würfel, A., Hill, C., Brockmann, N., Gáspár, R., Pálóczi, J., Varga, Z. V., Sárközy, M., Bencsik, P., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26052-w · Cited by 21
Therapeutic effects of Aconiti Lateralis Radix Praeparata combined with Zingiberis Rhizoma on doxorubicin-induced chronic heart failure in rats based on an integrated approach
Wen, J., Li, R., Wang, J., Hao, J.-J., Qin, W., Yang, T., Wang, R., Wei, S., Liu, X., Li, H.-T., et al. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13191 · Cited by 21
“As effective treatment of CHF could not only improve the survival and living quality of patients, but also reduce the economic burden of family and society,([7]) it is necessary to develop an efficient and economical therapeutic tool for the prevention and treatment of CHF.”
Background
The historical evolution of knowledge of the involvement of neurohormonal systems in the pathophysiology and treatment of heart failure
Polónia, J. J., & Rocha‐Gonçalves, F. (2019) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2020.02.006 · Cited by 20
“It is estimated that 23 million people worldwide have the condition.(11,12) Although its incidence appears to have stabilized in recent years, its prevalence continues to rise, due to aging populations, improvements in treatment and hence increased survival in HF and other cardiovascular diseases, and increased preval…”
Background
Management of Heart Failure in a Resource-Limited Setting: Expert Opinion from India
Jain, P., Guha, S., Kumar, S., Sawhney, J. P. S., Sharma, K. H., Sureshkumar, K. P., Mehta, A., Dhediya, R., Gaurav, K., Mittal, R., et al. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00367-4 · Cited by 24
“Heart failure (HF) is a significant global health issue affecting 23 million individuals world-wide [1], with a reported prevalence of 1.2 per 1000 people in India, according to the INDia Ukieri Study (INDUS) study [2].”
BackgroundInfluential
Demographic trends and disparities in mortality related to coexisting heart failure and diabetes mellitus among older adults in the United States between 1999 and 2020: A retrospective population-based cohort study from the CDC WONDER database
Saeed, H., Abdullah, M. B. B. S., Naeem, I., Zafar, A., Ahmad, B., Islam, T. U., Rizvi, S. S., Kumari, N., Kirmani, S. G. A., Mansoor, F., et al. (2024) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2024.200326 · Cited by 20
“African Americans have also been found to have multiple etiologies linked to HF, including hypertension, DM, and coronary artery disease [43].”
Background
Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies
Jakubowiak, A. J., DeCara, J. M., & Mezzi, K. (2017) · Hematology · doi:10.1080/10245332.2017.1328165 · Cited by 20
“Patients with New York Heart Association Class III and IV heart failure, recent myocardial infarction, conduction abnormalities, angina, or uncontrolled arrhythmias may be at increased cardiovascular risk, and patients aged ≥75 years are at an increased risk of cardiac failure [26,27].”
Background
Comparative Effectiveness of Low-Volume Time-Efficient Resistance Training Versus Endurance Training in Patients With Heart Failure
Munch, G. W., Rosenmeier, J. B., Petersen, M. A., Rinnov, A. R., Iepsen, U. W., Pedersen, B. K., & Mortensen, S. P. (2018) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000304 · Cited by 22
“After the first experimental day, patients were assigned (1:1 allocation ratio by sealed envelope lottery) to either (1) aerobic moderate-intensity cycling (AMC; n = 14) or (2) low-volume time-based resistance training (TRE; n = 14).”
MethodResult
Ambulatory Intra Aortic Balloon Pump in Advanced Heart Failure
Naqvi, S. Y., Salama, I. G., Yoruk, A., & Chen, L. (2018) · Cardiac failure review · doi:10.15420/cfr.2018:22:1 · Cited by 21
“Heart failure is a progressive and fatal disease that affects more than 23 million people worldwide, and will affect more than 8 million people in the USA by 2030.(1,2) Despite major advancements in medical and device treatments for heart failure in recent decades,”
Background
Bioinformatics Analysis and Identification of Genes and Pathways in Ischemic Cardiomyopathy
Cao, J., Liu, Z., Liu, J., Li, C., Zhang, G., & Shi, R. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s329980 · Cited by 20
Developing a core outcome set for patient-reported symptom monitoring to reduce hospital admissions for patients with heart failure
Lawson, C. A., Lam, C. S. P., Jaarsma, T., Kadam, U. T., Strömberg, A., Ali, M., Tay, W. T., Clayton, L., Khunti, K., & Squire, I. B. (2022) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvac019 · Cited by 18
Association of malnutrition with renal dysfunction and clinical outcome in patients with heart failure
Otaki, Y., Watanabe, T., Shimizu, M., Tachibana, S., Sato, J., Kobayashi, Y., Saito, Y., Aono, T., Tamura, H., Kato, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20985-z · Cited by 20
“The purposes of the present study were to (1) OPEN”
MethodResult
Prevalence, Incidence, Lifetime Risks, and Outcomes of Heart Failure in Asia
Hung, C., Chao, T., Tsai, C.-T., Liao, J., Lim, S., Tuan, T., Chen, T., Chan, Y., Chen, S., & Chiang, C. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.07.012 · Cited by 20
Sensitivity and Specificity of a Five-Minute Cognitive Screening Test in Patients With Heart Failure
Cameron, J., Gallagher, R. D., Pressler, S. J., McLennan, S. N., Ski, C. F., Tofler, G. H., & Thompson, D. R. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.08.343 · Cited by 20
Continuous flow left ventricular assist devices: a valid option for heart failure patients
Carrel, T. P., Englberger, L., Martinelli, M. V., Takala, J. A., Boesch, C., Sigurdadottir, V., Gygax, E., Kadner, A., & Mohaçsi, P. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13701 · Cited by 20
Incidence of Heart Failure in 6083 Elderly Hypertensive Patients: The Second Australian National Blood Pressure Study (ANBP2)
Sahle, B. W., Owen, A. J., Krum, H., & Reid, C. M. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.427 · Cited by 20
Effects of a nurse-led heart failure clinic on hospital readmission and mortality in Hong Kong.
Cheng, H. Y., Chair, S. Y., Wang, Q., Sit, J. W. H., Wong, E. M. L., & Tang, S. W. (2016) · PubMed Central · doi:10.11909/j.issn.1671-5411.2016.05.013 · Cited by 22
Critical Questions about PARADIGM-HF and the Future.
Chen, C. H. (2016) · Europe PMC (PubMed Central) · doi:10.6515/acs20151120a · Cited by 20
Spontaneous activation of a MAVS-dependent antiviral signaling pathway determines high basal interferon-β expression in cardiac myocytes
Rivera-Serrano, E. E., DeAngelis, N., & Sherry, B. (2017) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2017.08.008 · Cited by 19
Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program
Lopatin, Y. M., Cowie, M., Гребенникова, А., Sisakian, H. S., Pagava, Z., Hayrapetyan, H., Абдуллаев, Т. А., Voronkov, L. G., Chesnikova, A. I., Tseluyko, V., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.12.093 · Cited by 22
Can Computerized Cognitive Training Improve Cognition in Patients With Heart Failure?
Kua, Z. J., Valenzuela, M., & Dong, Y. (2018) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000558 · Cited by 20
Neurohumoral interactions contributing to renal vasoconstriction and decreased renal blood flow in heart failure
Ramchandra, R., Xing, D. T., Matear, M., Lambert, G. W., Allen, A. M., & May, C. N. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00026.2019 · Cited by 20
Psychological Disorders in Heart Failure
Palo, K. E. D. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.08.011 · Cited by 20
Identification of potential biomarkers for predicting the early onset of diabetic cardiomyopathy in a mouse model
Johnson, R., Nxele, X., Cour, M., Sangweni, N. F., Jooste, T., Hadebe, N., Samodien, E., Benjeddou, M., Mazino, M., Louw, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69254-x · Cited by 20
Sex-related differences in chronic heart failure: a community-based study
Russo, G. L., Rea, F., Barbati, G., Cherubini, A., Stellato, K., Scagnetto, A., Iorio, A., Corrao, G., & Lenarda, A. D. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001049 · Cited by 20
Designing Biomaterial Platforms for Cardiac Tissue and Disease Modeling
House, A. A., Atalla, I., Lee, E. J., & Güvendiren, M. (2020) · Advanced NanoBiomed Research · doi:10.1002/anbr.202000022 · Cited by 20
Higher urinary nitrate was associated with lower prevalence of congestive heart failure: results from NHANES
Wu, Z., Tian, T., Ma, W., Gao, W., & Song, N. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01790-w · Cited by 20
Limb-bud and Heart (LBH) mediates proliferation, fibroblast-to-myofibroblast transition and EMT-like processes in cardiac fibroblasts
Wu, A., Zhang, L., Chen, J., Li, H., Yang, P., Chen, M., & Liu, Q. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04111-7 · Cited by 20
Diagnostic Accuracy of Cognitive Screening Instruments in Heart Failure
Cameron, J., Kure, C., Pressler, S. J., Ski, C. F., Clark, A. M., & Thompson, D. R. (2015) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000285 · Cited by 21
“KEY WORDS: heart failure, mild cognitive impairment, neuropsychological test, review, screening In an aging population, there is no more relevant chronic cardiovascular health problem than heart failure (HF), which is estimated to currently affect 23 million individuals worldwide and will continue to be a major public…”
Background
Optimizing Machine Learning Classifiers for Enhanced Cardiovascular Disease Prediction
Alanazi, S. M., & Khamis, G. S. M. (2024) · Engineering Technology & Applied Science Research · doi:10.48084/etasr.6684 · Cited by 19
Advances in heart failure: a review of biomarkers, emerging pharmacological therapies, durable mechanical support and telemonitoring
Moayedi, Y., & Ross, H. J. (2017) · Clinical Science · doi:10.1042/cs20160196 · Cited by 19
Addressing the Heterogeneity of Heart Failure in Future Randomized Trials
Iorio, A., Pozzi, A., & Senni, M. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0332-1 · Cited by 19
Hepatocyte Growth Factor and Incident Heart Failure Subtypes: The Multi-Ethnic Study of Atherosclerosis (MESA)
Ferraro, R., Ogunmoroti, O., Zhao, D., Ndumele, C. E., Rao, V. N., Pandey, A., Larson, N. B., Bielinski, S. J., & Michos, E. D. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.04.022 · Cited by 19
Association Between Cholinesterase Inhibitors and New-Onset Heart Failure in Patients With Alzheimer's Disease: A Nationwide Propensity Score Matching Study
Hsieh, M., Chen, D., Lee, C., Wu, C.-L., Chen, Y.-J., Huang, Y., & Chang, S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.831730 · Cited by 19
“The incidences of HF and AD increase with age (1), but the incidence of new-onset HF in patients with AD has never been examined.”
Background
Depressive Symptoms and Quality of Life in Patients With Heart Failure and an Implantable Cardioverter-Defibrillator
Zormpas, C., Kahl, K. G., Hohmann, S., Oswald, H., Stiel, C., Veltmann, C., Bauersachs, J. K., & Duncker, D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.827967 · Cited by 19
Heart Disease Classification–Based on the Best Machine Learning Model
Rahma, M. M., & Salman, A. D. (2022) · Iraqi Journal of Science · doi:10.24996/ijs.2022.63.9.28 · Cited by 19
“As a result, cardiac failure arises [1].”
Safety and Efficacy of MitraClip in Acutely Ill (NYHA Class IV) Patients with Mitral Regurgitation: Results from the Global EXPAND Study
Shuvy, M., von Bardeleben, R. S., Grasso, C., Raake, P. W. J., Lurz, P. C., Zamorano, J. L., Asch, F. M., Kar, S., Maisano, F., & EXPAND Investigators (2023) · ESC Heart Failure · doi:10.1002/ehf2.14273 · Cited by 19
“Heart failure (HF) is a major health problem that is characterized by the worsening of symptoms and clinical deterioration.(1) Due to the increase in life expectancy and the evolution of therapy, a higher proportion of patients reach a more advanced stage of disease.”
Background
Adducin Regulates Sarcomere Disassembly During Cardiomyocyte Mitosis
Xiao, F., Nguyen, N. U. N., Wang, P., Li, S., Hsu, C., Thet, S., Kimura, W., Luo, X., Lam, N. T., Menendez-Montes, I., et al. (2024) · Circulation · doi:10.1161/circulationaha.122.059102 · Cited by 19
Risk stratification and short-term prognosis in acute heart failure syndromes: A review of novel biomarkers
Avellino, A., Collins, S. P., & Fermann, G. J. (2011) · Biomarkers · doi:10.3109/1354750x.2011.574234 · Cited by 19
Yoga for improving functional capacity, quality of life and cardiovascular outcomes in people with heart failure
Khatib, M. N., Kirubakaran, R., Gaidhane, S., Shankar, A. H., & Zahiruddin, Q. S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012015.pub2 · Cited by 19
CardioMEMS HF for the Management of Heart Failure—Effectiveness and Value
Ollendorf, D. A., Sandhu, A. T., & Pearson, S. D. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.5467 · Cited by 19
“atic processes for patient-clinician interaction; and (2) prioritiza-”
Background
The Benefit of Donor-Recipient Matching for Patients Undergoing Heart Transplantation
Nguyen, V. P., Mahr, C., Mokadam, N. A., Pal, J. D., Smith, J. W., & Dardas, T. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.038 · Cited by 19
Central-acting therapeutics alleviate respiratory weakness caused by heart failure–induced ventilatory overdrive
Foster, A., Platt, M. J., Huber, J. S., Eadie, A. L., Arkell, A. M., Romanova, N. A., Wright, D. C., Gillis, T. E., Murrant, C. L., Brunt, K. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1303 · Cited by 19
Sleep-Disordered Breathing in Heart Failure ― A Therapeutic Dilemma ―
Haruki, N., & Floras, J. S. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0440 · Cited by 21
Characterization of Cardiovascular Diseases Using Wavelet Packet Decomposition and Nonlinear Measures of Electrocardiogram Signal
Fujita, H., Sudarshan, V. K., Adam, M., Oh, S. L., Tan, J. H., Hagiwara, Y., Chua, K. C., Chua, K. P., & Acharya, U. R. (2017) · Lecture notes in computer science · doi:10.1007/978-3-319-60042-0_30 · Cited by 19
Temperature-sensitive sarcomeric protein post-translational modifications revealed by top-down proteomics
Cai, W., Hite, Z., Lyu, B., Wu, Z., Lin, Z., Gregorich, Z. R., Messer, A. E., McIlwain, S. J., Marston, S. B., Kohmoto, T., et al. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.07.247 · Cited by 17
Lung and cardiac ultrasound (LuCUS) protocol in diagnosing acute heart failure in patients with acute dyspnea
Dehbozorgi, A., Nejad, S. E., Mousavi‐Roknabadi, R. S., Sharifi, M., Tafakori, A., & Jalli, R. (2019) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2019.02.040 · Cited by 19
“As systolic heart failure is more common than diastolic heart failure [22,23], we did not differentiate systolic and diastolic heart failure, which is one of the limitation of this study.”
Background
Predictive Value of Endoplasmic Reticulum Stress Markers in Low Ejection Fractional Heart Failure
Sabırlı, R., Köseler, A., MANSUR, N., Zeytünlüoğlu, A., Sabirli, G. T., Türkçüer, İ., & Kılıç, İ. D. (2019) · In Vivo · doi:10.21873/invivo.11640 · Cited by 19
Prognostic value of ankle brachial index for future incident heart failure in patients without previous heart failure: data from the impressive predictive value of ankle brachial index for clinical long term outcome in patients with cardiovascular disease examined by ABI study
Nishimura, H., Miura, T., Minamisawa, M., Ueki, Y., Abe, N., Hashizume, N., Mochidome, T., Harada, M., Shimizu, K., Shoin, W., et al. (2016) · Heart and Vessels · doi:10.1007/s00380-016-0873-3 · Cited by 19
Epicardial delivery of autologous atrial appendage micrografts during coronary artery bypass surgery—safety and feasibility study
Nummi, A., Nieminen, T. V. M., Pätilä, T., Lampinen, M., Lehtinen, M. L., Kivistö, S., Holmström, M., Wilkman, E., Teittinen, K., Laine, M., et al. (2017) · Pilot and Feasibility Studies · doi:10.1186/s40814-017-0217-9 · Cited by 19
“In conclusion, given the severe problems associated with heart failure and its increasing high prevalence [50] in the elderly population, it is of utmost importance to devise effective novel evidence-based cell therapies.”
Background
Exposure of Ldlr−/− Mice to a PFAS Mixture and Outcomes Related to Circulating Lipids, Bile Acid Excretion, and the Intestinal Transporter ASBT
Roth, K., Yang, Z., Agarwal, M., Birbeck, J. A., Westrick, J. A., Lydic, T. A., Gurdziel, K., & Petriello, M. C. (2024) · Environmental Health Perspectives · doi:10.1289/ehp14339 · Cited by 20
Epidemiology of geographic disparities in heart failure among US older adults: a Medicare-based analysis
Yu, B., Akushevich, I. V., Yashkin, A. P., Yashin, A. I., Lyerly, H. K., & Kravchenko, J. S. (2022) · BMC Public Health · doi:10.1186/s12889-022-13639-2 · Cited by 18
Relationship between serum sodium levels and all-cause mortality in congestive heart failure patients: A retrospective cohort study based on the Mimic-III database
Peng, S., Peng, J., Yang, L., & Ke, W. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1082845 · Cited by 18
“In turn, hyponatremia encourages greater RAAS activation, starting a vicious cycle (10).”
Background
Meteorin-like (METRNL) attenuates hypertensive induced cardiac hypertrophy by inhibiting autophagy via activating BRCA2
Li, J., Hong, Y., Zhong, Y., Yang, S., Pei, L., Huang, Z., Long, H., Chen, X., Zhou, C., Zheng, G., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167113 · Cited by 17
Usability Testing of an Internet-Based e-Counseling Platform for Adults With Chronic Heart Failure
Payne, A. Y. M., Surikova, J., Liu, S., Ross, H. J., Mechetiuc, T., & Nolan, R. P. (2015) · JMIR Human Factors · doi:10.2196/humanfactors.4125 · Cited by 18
“It is a major cause of hospitalization and mortality, and it is increasing in prevalence [2].”
Background
Resource use and costs in systolic heart failure according to disease severity: a pooled analysis from the German Competence Network Heart Failure
Biermann, J., Neumann, T., Angermann, C. E., Düngen, H., Erbel, R. M., Herzog, W., Maisch, B., Müller‐Tasch, T., Özcelik, C., Pankuweit, S., et al. (2011) · Journal of Public Health · doi:10.1007/s10389-011-0452-0 · Cited by 18
Mechanical Circulatory Support and the Role of LVADs in Heart Failure Therapy
McLarty, A. J. (2015) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s19694 · Cited by 48
“8 Current indications for LVAD implantation as DT include patients (1) with New”
Background
The TNF-α/Sphingosine-1-Phosphate Signaling Axis Drives Myogenic Responsiveness in Heart Failure
Kroetsch, J. T., & Bolz, S. (2013) · Journal of Vascular Research · doi:10.1159/000350528 · Cited by 18
Past and Present of Total Artificial Heart Therapy: A Success Story
Samak, M., Fatullayev, J., Sabashnikov, A., Zeriouh, M., Rahmanian, P. B., Choi, Y., Wippermann, J., Wahlers, T., Schmack, B., Ruhparwar, A., et al. (2015) · Medical science monitor basic research/Medical science monitor. Basic research · doi:10.12659/msmbr.895418 · Cited by 18
“It is estimated that 1 in every 5 people will develop HF in their lifetime, a risk notoriously known to increases with age [3].”
Background
Matrix Metalloproteinase-2 Polymorphisms in Chronic Heart Failure: Relationship with Susceptibility and Long-Term Survival
Beber, A. R. C., Polina, E. R., Biolo, A., dos Santos, B. L., Gomes, D. D. C., Porta, V. L. L., Olsen, V. D. R., Clausell, N., Rohde, L. E. P., & dos Santos, K. G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161666 · Cited by 18
“Heart failure (HF) is a clinical syndrome of insufficient cardiac output resulting from myocardial injury that remains a leading cause of morbidity and mortality worldwide [1,2].”
Background

Authors: Bui, A. L., Horwich, T. B., & Fonarow, G. C.
Affiliations: University of California, Los Angeles (US)
Corresponding author: Fonarow, Gregg C.
ORCID: Horwich, Tamara B.
Fonarow, Gregg C.
Venue: Nature Reviews Cardiology
Publisher: Springer Science and Business Media LLC
Published: 2010-11-09
Volume: 8
Issue: 1
Pages: 30-41
ISSN: 1759-5002 (ISSN-L)
1759-5010
DOI: 10.1038/nrcardio.2010.165
PMC: PMC3033496
OpenAlex: W1992644002
Cited by: 2,077
References: 144
Citations by year: 2026: 48 · 2025: 91 · 2024: 126 · 2023: 158 · 2022: 173 · 2021: 186 · 2020: 209 · 2019: 169 · 2018: 191 · 2017: 211 · 2016: 174 · 2015: 121 · 2014: 91 · 2013: 60 · 2012: 46
FWCI: 6.84
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Reviews Cardiology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Heart Failure Society of America
Ahmanson Foundation
National Institutes of Health (5k23hl085097-04)
National Heart, Lung, and Blood Institute (1K23HL085097, K23 HL085097, T32HL007895)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords: heart failure, heart failure epidemiology, heart failure risk factors, heart failure prevalence, heart failure mortality, health care costs, ischemic heart disease, hypertension, smoking, obesity, diabetes mellitus
MeSH terms: Adult, Aged, Female, Heart Failure, Humans, Male, Middle Aged, Prognosis, Risk Factors, Time Factors, Incidence, Prevalence, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology and risk profile of heart failure

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks